Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Stopped Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.

Conditions

• Tetanus
• Poliomyelitis
• Neisseria Meningitidis
• Haemophilus Influenzae Type b
• Diphtheria
• Acellular Pertussis
• Hepatitis B

Interventions

• BIOLOGICAL: GSK2202083A vaccine
• BIOLOGICAL: Infanrix hexa
• BIOLOGICAL: Menjugate

Sponsor

GlaxoSmithKline